These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

57 related articles for article (PubMed ID: 28880441)

  • 1. Letter: CYP2C19 polymorphisms and exacerbation of rabeprazole's effects on celecoxib-induced small bowel injury-authors' reply.
    Nuki Y; Esaki M
    Aliment Pharmacol Ther; 2017 Oct; 46(7):708. PubMed ID: 28880441
    [No Abstract]   [Full Text] [Related]  

  • 2. Letter: CYP2C19 polymorphisms and exacerbation of rabeprazole's effects on celecoxib-induced small bowel injury.
    Srinivas NR
    Aliment Pharmacol Ther; 2017 Oct; 46(7):706-707. PubMed ID: 28880446
    [No Abstract]   [Full Text] [Related]  

  • 3. The influence of CYP2C19 polymorphisms on exacerbating effect of rabeprazole in celecoxib-induced small bowel injury.
    Nuki Y; Umeno J; Washio E; Maehata Y; Hirano A; Miyazaki M; Kobayashi H; Kitazono T; Matsumoto T; Esaki M
    Aliment Pharmacol Ther; 2017 Aug; 46(3):331-336. PubMed ID: 28481007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CYP2C19 genotype and the PPIs--focus on rabeprazole.
    Lim PW; Goh KL; Wong BC
    J Gastroenterol Hepatol; 2005 Dec; 20 Suppl():S22-8. PubMed ID: 16359346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proton Pump Inhibitors Increase Incidence of Nonsteroidal Anti-Inflammatory Drug-Induced Small Bowel Injury: A Randomized, Placebo-Controlled Trial.
    Washio E; Esaki M; Maehata Y; Miyazaki M; Kobayashi H; Ishikawa H; Kitazono T; Matsumoto T
    Clin Gastroenterol Hepatol; 2016 Jun; 14(6):809-815.e1. PubMed ID: 26538205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the relationship between polymorphisms in CYP2C19 and the pharmacokinetics of omeprazole, pantoprazole and rabeprazole.
    Román M; Ochoa D; Sánchez-Rojas SD; Talegón M; Prieto-Pérez R; Rivas Â; Abad-Santos F; Cabaleiro T
    Pharmacogenomics; 2014; 15(15):1893-901. PubMed ID: 25495411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of cytochrome P450 2C19 polymorphisms on the Helicobacter pylori eradication rate following two-week triple therapy with pantoprazole or rabeprazole.
    Ormeci A; Emrence Z; Baran B; Gokturk S; Soyer OM; Evirgen S; Akyuz F; Karaca C; Besisik F; Kaymakoglu S; Ustek D; Demir K
    Eur Rev Med Pharmacol Sci; 2016 Mar; 20(5):879-85. PubMed ID: 27010145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of rabeprazole and lansoprazole on the pharmacokinetics of tacrolimus in relation to CYP2C19, CYP3A5 and MDR1 polymorphisms in renal transplant recipients.
    Miura M; Inoue K; Kagaya H; Satoh S; Tada H; Sagae Y; Habuchi T; Suzuki T
    Biopharm Drug Dispos; 2007 May; 28(4):167-75. PubMed ID: 17377957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole.
    Sahara S; Sugimoto M; Uotani T; Ichikawa H; Yamade M; Iwaizumi M; Yamada T; Osawa S; Sugimoto K; Umemura K; Miyajima H; Furuta T
    Aliment Pharmacol Ther; 2013 Nov; 38(9):1129-37. PubMed ID: 24099474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of Proton Pump Inhibitors on Mycophenolic Acid Pharmacokinetics in Patients With Renal Transplantation and the Relationship With Cytochrome 2C19 Gene Polymorphism.
    Ciftci HS; Karadeniz MS; Tefik T; Caliskan Y; Yazıcı H; Demir E; Turkmen A; Nane I; Oguz FS; Aydin F
    Transplant Proc; 2017 Apr; 49(3):490-496. PubMed ID: 28340819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enantioselective disposition of rabeprazole in relation to CYP2C19 genotypes.
    Miura M; Kagaya H; Tada H; Uno T; Yasui-Furukori N; Tateishi T; Suzuki T
    Br J Clin Pharmacol; 2006 Mar; 61(3):315-20. PubMed ID: 16487225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of lansoprazole and rabeprazole on tacrolimus pharmacokinetics in healthy volunteers with CYP2C19 mutations.
    Itagaki F; Homma M; Yuzawa K; Nishimura M; Naito S; Ueda N; Ohkohchi N; Kohda Y
    J Pharm Pharmacol; 2004 Aug; 56(8):1055-9. PubMed ID: 15285851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CYP2C19 genetic polymorphism, rabeprazole and esomeprazole have no effect on the antiplatelet action of clopidogrel.
    El-Halabi MM; Zgheib N; Mansour NM; Malli A; Ghaith OA; Mahfouz R; Alam S; Sharara AI
    J Cardiovasc Pharmacol; 2013 Jul; 62(1):41-9. PubMed ID: 23474843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparative study on endoscopic ulcer healing of omeprazole versus rabeprazole with respect to CYP2C19 genotypic differences.
    Ando T; Kato H; Sugimoto N; Nagao Y; Seto N; Hongo H; Kajikawa H; Isozaki Y; Shimozawa M; Naito Y; Yoshida N; Ishizaki T; Yoshikawa T
    Dig Dis Sci; 2005 Sep; 50(9):1625-31. PubMed ID: 16133961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection in relation to CYP2C19 genotype.
    Lee SB; Park SJ; Ryu JK; Lee JK; Kim HJ; Bae JS; Jung HS; Park SM
    Korean J Gastroenterol; 2003 Dec; 42(6):468-75. PubMed ID: 14695703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis.
    Padol S; Yuan Y; Thabane M; Padol IT; Hunt RH
    Am J Gastroenterol; 2006 Jul; 101(7):1467-75. PubMed ID: 16863547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis.
    Zhao F; Wang J; Yang Y; Wang X; Shi R; Xu Z; Huang Z; Zhang G
    Helicobacter; 2008 Dec; 13(6):532-41. PubMed ID: 19166419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma concentration of rabeprazole after 8-week administration in gastroesophageal reflux disease patients and intragastric pH elevation.
    Yamano HO; Matsushita HO; Yanagiwara S
    J Gastroenterol Hepatol; 2008 Apr; 23(4):534-40. PubMed ID: 17725594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rabeprazole can overcome the impact of CYP2C19 polymorphism on quadruple therapy.
    Kuo CH; Wang SS; Hsu WH; Kuo FC; Weng BC; Li CJ; Hsu PI; Chen A; Hung WC; Yang YC; Wang WM; Wu DC
    Helicobacter; 2010 Aug; 15(4):265-72. PubMed ID: 20633187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. One-day front-loading with four doses of rabeprazole followed by a standard twice-daily regimen provides sufficient acid inhibition in extensive metabolizers of CYP2C19.
    Kagami T; Sugimoto M; Ichikawa H; Sahara S; Uotani T; Yamade M; Hamaya Y; Iwaizumi M; Osawa S; Sugimoto K; Miyajima H; Furuta T
    Eur J Clin Pharmacol; 2015 Dec; 71(12):1467-75. PubMed ID: 26427705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.